ALSO NOTED: Genentech selling senior notes; Hi-tech buys Zostrix rights; Corixa shareholders approve takeover; and much more...

> Genentech is offering $2 billion in senior notes to upgrade facilities, fund R&D and for other purposes. Story

> Hi-Tech Pharmacal of Amityville, New York, has acquired the US rights to the brands Zostrix and Zostrix HP, topical analgesic creams from Rodlen Laboratories. Release

> Seattle-based Corixa announced that its shareholders have approved a takeover by GlaxoSmithKline. Story

> Vitae Pharmaceuticals has secured $15 million in financing. Release

And Finally... In the first survey of its kind, researchers found that at least 12,000 Pennsylvanians contracted a hospital infection, costing an extra $2 billion in care and leading to 1,500 preventable deaths. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.